KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Equity Income (2016 - 2025)

Jazz Pharmaceuticals has reported Equity Income over the past 10 years, most recently at -$57000.0 for Q4 2025.

  • Quarterly Equity Income fell 256.25% to -$57000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$206000.0 through Dec 2025, up 87.59% year-over-year, with the annual reading at -$732000.0 for FY2025, 55.9% up from the prior year.
  • Equity Income was -$57000.0 for Q4 2025 at Jazz Pharmaceuticals, down from -$47000.0 in the prior quarter.
  • Over five years, Equity Income peaked at $4.2 million in Q1 2021 and troughed at -$4.1 million in Q1 2022.
  • The 5-year median for Equity Income is -$461000.0 (2023), against an average of -$815473.7.
  • Biggest five-year swings in Equity Income: skyrocketed 2188.46% in 2021 and later plummeted 616.67% in 2025.
  • Tracing JAZZ's Equity Income over 5 years: stood at -$3.0 million in 2021, then soared by 74.13% to -$773000.0 in 2022, then soared by 40.36% to -$461000.0 in 2023, then surged by 96.53% to -$16000.0 in 2024, then plummeted by 256.25% to -$57000.0 in 2025.
  • According to Business Quant data, Equity Income over the past three periods came in at -$57000.0, -$47000.0, and -$86000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.